HOME COMPANY TECHNOLOGIES R&D NEWS CONTACT US FROM RARE ANTIBODIES TO INNOVATIVE THERAPEUTICS Best in class therapeutic antibodies for the treatment of cancer BliNK Biomedical SAS specializes in the discovery and development of first or best-in-class antibody-based therapeutics for life threatening diseases such as cancer with a focus on immuno-oncology disease targets. Our lead program is a monoclonal antibody that targets an immune checkpoint to cause an immune switch that renders tumors susceptible to the body's immune system. Our other programs address a number of attractive, novel immuno-oncology and immune-checkpoint targets, some of which are unique to our approach. The antibodies that we are developing have the potential to be the next generation of anti-tumor therapeutics. BliNK Biomedical's powerful B cell technology enables us to selectively isolate specific antibody producing cells for difficult targets. This cutting-edge technology, based on our validated platforms (IVV, ISAAC and VIVA|Screen®), constitute a highly efficient and deep mining process and provides an unprecedented capability to identify very rare antibody-secreting cells from human and non-human species. This unique capability represents a major advantage compared to other technologies, enabling us to identify a unique generation of therapeutic antibodies. Our headquarters are in Lyon (France) and we have a subsidiary, BliNK Therapeutics, in Stevenage (UK). HOME COMPANY TECHNOLOGIES R&D NEWS CONTACT US WEBSITE INFO GERLAND PLAZA TECHSUD | 70, RUE SAINT-JEAN-DE-DIEU | 69007 LYON - FRANCE INFO@BLINKBIOMEDICAL.COM © BLINK BIOMEDICAL SAS WEBDESIGN : PASCAL BONDU GREENCITRUS : CRÉATION DE SITE INTERNET À LYON